Kyverna Therapeutics, Inc. KYTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s additional paid-in capital?
- Kyverna Therapeutics, Inc. (KYTX) reported additional paid-in capital of $660.23M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Kyverna Therapeutics, Inc.'s additional paid-in capital increased by 24.1% year-over-year, from $532.17M to $660.23M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s additional paid-in capital has grown at a 1089.7% compound annual growth rate (CAGR), from $4.64M to $657.01M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.